Zacks Investment Research upgraded shares of Pharma Mar (OTCMKTS:PHMMF) from a sell rating to a hold rating in a report released on Wednesday, September 12th.
According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “
Shares of OTCMKTS PHMMF traded down $0.09 during midday trading on Wednesday, reaching $1.71. 2,000 shares of the company’s stock traded hands, compared to its average volume of 8,821. Pharma Mar has a one year low of $1.64 and a one year high of $3.93.
About Pharma Mar
Pharma Mar, SA, a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally. The company operates through two segments, Biopharmaceuticals and Consumer Chemicals. It develops and commercializes YONDELIS, an antitumor agent for the treatment of advanced soft tissue sarcomas and for relapsed ovarian cancer.
Recommended Story: Determine Your Level of Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.